- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01702103
Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays (PHT-01-12)
MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED, CLINICAL STUDY TO DEMONSTRATE THE THERAPEUTIC CLINICAL EQUIVALENCE OF TWO MOMETASONE NASAL SPRAYS IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Perennial allergic rhinitis may be defined clinically as an inflammatory condition of the nose characterised by nasal obstruction, sneezing, itching, or rhinorrhoea. It occurs due to an exaggerated response to an environmental trigger which results in inflammation of the lining of the nose; it is similar to hayfever, however, the substances which cause the allergic reaction are present all year round; common causes include the faecal matter of the house dust-mite (Dermatophagoides pteronyssinus), animal proteins from domestic pets (saliva or skin proteins), and industrial dusts and fumes In those with perennial rhinitis, cigarette smoke, washing powders, detergents, strong perfume, and traffic fumes may exacerbate the condition.
According with WAO (World Allergy Organization), perennial rhinitis predominates in South America, Asia, Africa and Australia; perennial and seasonal rhinitis occur commonly in the U.S.A. and Japan. Seasonal rhinitis predominates in Europe. In one study in London of adults between the ages of 16 and 65 years, in 1991 the prevalence of rhinitis was 16%; of these, 8% had perennial symptoms, 6% perennial and seasonal symptoms, and 2% seasonal symptoms alone. As with asthma, both seasonal and perennial rhinitis seem to be increasing. The 2004-05 National Health Survey stated that 3.2 million Australians (approximately 16.1% of the population) self-reported experiencing symptoms of hay-fever and perennial rhinitis. The prevalence was found to be highest amongst those aged 25-34 and was slightly higher among females (1.7 million) than males (1.5 million).
Perennial allergic rhinitis (PAR) as seasonal allergic rhinitis (SAR) result from an immunological response mediated by IgE; there is also a Th2 cell component accounting for chronic symptoms. Histamine is a well-known mediator responsible for the signs and symptoms of SAR but many other mediators including leukotrienes and prostaglandin D2 are involved.
The management of perennial rhinitis involves the avoidance of triggers such as house dust-mite faeces and animal proteins, in conjunction with pharmacological treatments as:
Corticosteroids as Budesonide, Mometasone furoate, in the form of a nasal spray are the first-line treatment for perennial allergic rhinitis.
Antihistamines as Cetirizine hydrochloride, Fexofenadine hydrochloride, work by blocking the effects of histamine which is one of the main substances driving allergic reactions.
Decongestants as Phenylephrine hydrochloride, may be taken orally or as a nasal spray to reduce the secretions and swelling of the lining of the nose by constricting the blood vessels in the nose. Anti-inflammatories as Sodium cromoglycate, block the inflammatory pathways that cause the symptoms of perennial rhinitis, however, they have not been found to be more effective than corticosteroids or antihistamines.
Eye drops as Ketotifen fumarate, Hydrocortisone acetate, may be used to control symptoms such as itchy or watery eyes.
Allergen desensitisation involves exposing the patient to small doses of allergens in an attempt to desensitize them and prevent an allergic response.
Corticosteroids, as reported above, in the form of a nasal spray are the first-line treatment for perennial allergic rhinitis; one of the most widely used is mometasone furoate. A meta-analysis of randomized, double blind, placebo controlled, clinical trials on mometasone furoate nasal spray in the treatment of allergic rhinitis, by a comprehensive search of the MEDLINE, LILACS, SCOPUS, and the Cochrane Library databases up to 31 October, 2007 was carried out. Meta-analysis was performed with the random or the fixed effect models depending on heterogeneity, by using revman 5 software on the sixteen of the 113 identified articles that met the inclusion criteria. This meta-analysis provides a level Ia evidence for the efficacy of MFSN in the treatment vs placebo, with adverse events frequency similar in both groups.
On this basis we decided to design a trial to show therapeutic equivalence of a generic mometasone product with the drug Nasonex® Nasal Spray which is already marketed.
Number of patients: 298 completed patients with Perennial Allergic Rhinitis are required in this study; with a planned drop-out rate of 20%, 360 patients have to be enrolled.
Main Inclusion Criteria: Male and female, 12 years until 65 years old. Subjects with a minimum of 2 years of previous history of perennial allergic rhinitis to at least one perennial allergen at the time the study is being conducted.
Signed informed consent form. For patients under the age of majority the parent or legal guardian should sign the consent form and the child will be required to sign a patient "assent" form.
Subjects with perennial allergic rhinitis documented in writing positive allergic skin (a wheal >3mm) test or positive RAST test, performed at screening or within the past 12 months.
A score of at least 6 on the TNSS with a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms.
Subjects capable of recording nasal allergy diary every day. Main Exclusion Criteria: Females who are pregnant, lactating or plan to get pregnant during the study.
History of asthma over the previous two years that required chronic therapy (with the exception of occasional acute or mild exercise induced asthma).
Patients with some nasal conditions (i.e. infectious sinusitis, hypertrophic rhinitis), or with clinically significant nasal deformity or any recent nasal surgery or trauma that has not completely healed.
Upper respiratory tract infection or any untreated systemic infections within the previous 30 days.
Patients previously treated with mometasone within the previous 30 days Patients who have received anti-allergy immunotherapy (desensitising subjects with increase of allergen challenges) in the previous 2 years or are still receiving this kind of therapy.
Patients with a history of tuberculosis. Patients with glaucoma, cataracts, ocular herpes simplex, conjunctivitis or other eye infection.
The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.
Any known hypersensitivity to mometasone, other steroids or any of the components of the study nasal spray.
Planned travel outside of the local area for more than 2 consecutive days or 3 days in total.
The patient has a history of alcohol or drug abuse.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Capital Federal
-
Buenos Aires, Capital Federal, Argentina, C1118AAE
- Swiss Medical Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male and female, 12 years until 65 years old. Subjects with a minimum of 2 years of previous history of perennial allergic rhinitis to at least one perennial allergen at the time the study is being conducted.
Signed informed consent form. For patients under the age of majority the parent or legal guardian should sign the consent form and the child will be required to sign a patient "assent" form.
Subjects with perennial allergic rhinitis documented in writing positive allergic skin (a wheal >3mm) test or positive RAST test, performed at screening or within the past 12 months.
A score of at least 6 on the TNSS with a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms.
Subjects capable of recording nasal allergy diary every day.
Exclusion Criteria:
Females who are pregnant, lactating or plan to get pregnant during the study. History of asthma over the previous two years that required chronic therapy (with the exception of occasional acute or mild exercise induced asthma).
Patients with some nasal conditions (i.e. infectious sinusitis, hypertrophic rhinitis), or with clinically significant nasal deformity or any recent nasal surgery or trauma that has not completely healed.
Upper respiratory tract infection or any untreated systemic infections within the previous 30 days.
Patients previously treated with mometasone within the previous 30 days Patients who have received anti-allergy immunotherapy (desensitising subjects with increase of allergen challenges) in the previous 2 years or are still receiving this kind of therapy.
Patients with a history of tuberculosis. Patients with glaucoma, cataracts, ocular herpes simplex, conjunctivitis or other eye infection.
The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.
Any known hypersensitivity to mometasone, other steroids or any of the components of the study nasal spray.
Planned travel outside of the local area for more than 2 consecutive days or 3 days in total.
The patient has a history of alcohol or drug abuse.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mometasone
Mometasone, nasal spray for 8 weeks, 2 actuations each nostril in the morning.
|
|
Active Comparator: Nasonex®
Nasonex nasal spray for 8 weeks 2 actuations each nostril in the morning.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
demonstrate the therapeutic clinical equivalence of two mometasone nasal sprays in the relief of the signs and symptoms of perennial allergic rhinitis, in term of changes at week 8 from baseline of Total Nasal Symptom Scores (TNSS).
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety monitoring AE, routine laboratory haematology, biochemical tests, urinalysis, assessment of adrenal function to be sure of lack of systemic effect of nasal spray formulation Overall Patient's and Physician's global assessment.
Time Frame: 8 weeks
|
Patients at week 8 with a 50% reduction in TNSS mean change from baseline. Symptom-free days. The mean change from baseline to week 8 for mean Total Non Nasal Symptom Scores (TNNSS). Use of rescue medication (Time Frame: 8 weeks). Individual patient-rated symptoms evaluation. Clinical Global Improvement (CGI) evaluation. Treatment compliance: That includes description of the patient's adherence to the optimal prolonged treatment. |
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Alessandro Mazzetti, MD, Sintesi Research Srl
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHT-01-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasal Obstruction
-
Spirair, IncRecruitingNasal Airway Obstruction | Nasal Septal DeviationUnited States
-
Aerin MedicalOhio State UniversityCompletedNasal ObstructionUnited States
-
Aerin MedicalActive, not recruitingNasal ObstructionUnited States
-
Medtronic Surgical TechnologiesCompletedNasal Airway ObstructionUnited States, Canada
-
Aerin MedicalActive, not recruitingNasal Airway ObstructionUnited States
-
New York City Health and Hospitals CorporationUnknownNasal Airway ObstructionUnited States
-
Yuzuncu Yıl UniversityCompleted
-
Aerin MedicalCompletedNasal ObstructionUnited States
-
Aerin MedicalCompleted
-
HNO-Praxis Alte PostAerin MedicalCompletedNasal Obstruction, BilateralGermany
Clinical Trials on Mometasone furoate
-
Teva Pharmaceuticals USACompletedSeasonal Allergic Rhinitis
-
Padagis LLCCompleted
-
Eurofarma Laboratorios S.A.CompletedMild to Moderate Persistent Allergic RhinitisBrazil
-
Massachusetts General HospitalMerck Sharp & Dohme LLC; Massachusetts Eye and Ear InfirmaryTerminatedNasal PolypsUnited States
-
Montefiore Medical CenterWithdrawnRadiation DermatitisUnited States
-
University of FloridaGlaxoSmithKline; Food and Drug Administration (FDA)CompletedHypersensitivityUnited States
-
Novartis PharmaceuticalsCompletedMild AsthmaGermany, India, Korea, Republic of, Poland, South Africa, Estonia, Italy, Russian Federation, Thailand, Latvia, Lithuania, Colombia, Hungary, Peru, Philippines, Slovakia, Bulgaria, Vietnam, Japan, Malaysia, Chile, Sweden
-
GlaxoSmithKlineCompleted
-
Novartis PharmaceuticalsCompletedAsthmaGermany, Slovakia, Bulgaria, Canada, Poland, Korea, Republic of, Netherlands, Japan
-
James J. Peters Veterans Affairs Medical CenterKessler Institute for RehabilitationUnknownSpinal Cord InjuryUnited States